135 related articles for article (PubMed ID: 26882073)
1. Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Bhargava A; Pelech S; Woodard B; Kerwin J; Maherali N; ;
Elife; 2016 Feb; 5():. PubMed ID: 26882073
[TBL] [Abstract][Full Text] [Related]
2. Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Bhargava A; Anant M; Mack H; ;
Elife; 2016 Feb; 5():. PubMed ID: 26885666
[TBL] [Abstract][Full Text] [Related]
3. Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Sharma V; Young L; Cavadas M; Owen K;
Elife; 2016 Mar; 5():. PubMed ID: 26999821
[TBL] [Abstract][Full Text] [Related]
4. Registered report: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology.
Khan I; Kerwin J; Owen K; Griner E; ;
Elife; 2015 Sep; 4():. PubMed ID: 26335297
[TBL] [Abstract][Full Text] [Related]
5. Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers.
Sharma V; Young L; Allison AB; Owen K; ;
Elife; 2016 Feb; 5():. PubMed ID: 26894955
[TBL] [Abstract][Full Text] [Related]
6. Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
Haven B; Heilig E; Donham C; Settles M; Vasilevsky N; Owen K; ;
Elife; 2016 Feb; 5():. PubMed ID: 26905833
[TBL] [Abstract][Full Text] [Related]
7. Registered report: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment.
Evans J; Essex A; Xin H; Amitai N; Brinton L; Griner E; ;
Elife; 2015 Aug; 4():. PubMed ID: 26287525
[TBL] [Abstract][Full Text] [Related]
8. Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells.
Vanden Heuvel JP; Bullenkamp J;
Elife; 2016 Jun; 5():. PubMed ID: 27336789
[TBL] [Abstract][Full Text] [Related]
9. Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Blum D; LaBarge S;
Elife; 2014 Dec; 3():. PubMed ID: 25490933
[TBL] [Abstract][Full Text] [Related]
10. Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia.
Fung JJ; Kosaka A; Shan X; Danet-Desnoyers G; Gormally M; Owen K; ;
Elife; 2015 Sep; 4():. PubMed ID: 26327698
[TBL] [Abstract][Full Text] [Related]
11. Registered report: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
Lesnik J; Antes T; Kim J; Griner E; Pedro L; ;
Elife; 2016 Jan; 5():e07383. PubMed ID: 26826285
[TBL] [Abstract][Full Text] [Related]
12. Registered report: Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis.
Fiering S; Ang LH; Lacoste J; Smith TD; Griner E;
Elife; 2015 Jul; 4():e04796. PubMed ID: 26179155
[TBL] [Abstract][Full Text] [Related]
13. Registered report: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma.
Repass J; Maherali N; Owen K; ;
Elife; 2016 Feb; 5():. PubMed ID: 26882501
[TBL] [Abstract][Full Text] [Related]
14. Registered report: the microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.
Li J; Lam M;
Elife; 2015 Jul; 4():e06434. PubMed ID: 26231042
[TBL] [Abstract][Full Text] [Related]
15. Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.
Phelps M; Coss C; Wang H; Cook M; ;
Elife; 2016 Mar; 5():. PubMed ID: 26943900
[TBL] [Abstract][Full Text] [Related]
16. Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Evans B; Griner E;
Elife; 2015 Jul; 4():e07420. PubMed ID: 26231040
[TBL] [Abstract][Full Text] [Related]
17. Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors.
Greenfield E; Griner E;
Elife; 2014 Dec; 3():. PubMed ID: 25490934
[TBL] [Abstract][Full Text] [Related]
18. Registered report: IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Richarson AD; Scott DA; Zagnitko O; Aza-Blanc P; Chang CC; Russler-Germain DA;
Elife; 2016 Mar; 5():e10860. PubMed ID: 26971564
[TBL] [Abstract][Full Text] [Related]
19. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.
Holderfield M; Merritt H; Chan J; Wallroth M; Tandeske L; Zhai H; Tellew J; Hardy S; Hekmat-Nejad M; Stuart DD; McCormick F; Nagel TE
Cancer Cell; 2013 May; 23(5):594-602. PubMed ID: 23680146
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
